Avalo Therapeutics, Inc. (AVTX)

Market Cap	93.24M
Revenue (ttm)	807,000
Net Income (ttm)	-36.22M
Shares Out	9.68M
EPS (ttm)	-204.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,918
Open	9.52
Previous Close	9.60
Day's Range	9.51 - 9.99
52-Week Range	3.95 - 45.12
Beta	1.09
Analysts	Buy
Price Target	35.00 (+263.45%)
Earnings Date	Nov 7, 2024

About AVTX

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company’s drug candidates include AVTX-009, an Anti-IL-1β monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory dis...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 15, 2015
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: AVTX
• Website: https://www.avalotx.com

Financial Performance

In 2023, Avalo Therapeutics's revenue was $1.92 million, a decrease of -89.34% compared to the previous year's $18.05 million. Losses were -$31.54 million, -24.28% less than in 2022.

Analyst Forecast

According to one analyst, the rating for AVTX stock is "Buy" and the 12-month stock price forecast is $35.0.

Price Target

$35.0

(263.45% upside)

Analyst Consensus: Buy